Skip to content
Catalyst

Lentinula edodesFinding

Lentinula edodes increases patient survival rate

raisesModerate evidenceFinding

01 · The sentence it was drawn from

“There was s significant increase of survival rate in lentinan group compared with control in 1 year [RR, 1.46, 95% CI (1.16–1.84); P = 0.001], whereas no significant difference was found in 2 years [1.16 (0.85–1.56); P = 0.34]; as shown in Figure 3.”
Quoted verbatim from Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis.
This finding among the 1 finding on its endpoint

Lentinula edodes

Patient survival rate

raises

Effect as reported

1.46risk ratio

CI 1.16 to 1.84

Who
Patients with advanced solid tumours in pooled trials, lentinan added to chemotherapy versus chemotherapy alone; 1-year survival
Dose studied
1 mg or 2 mg per injection, from once daily to twice a month across trials

Moderate evidencePMID 28940986 · 2017

02 · The study

Study
meta-analysis
Duration
not reported

Evidence, by strength

  • strong
  • moderatethis finding
  • limited
  • very limited
  • insufficient

03 · The paper

Cancer medicine
What else it reported1 finding · 0 compounds · 1 endpoint

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M6ZMNF7PHTY74ZFN5ZYZYGZZ